Key result
Upfront ambrisentan plus tadalafil reduces clinical failure risk versus monotherapy in PAH.
Why the study?
Does ambrisentan improve outcomes in patients with pulmonary arterial hypertension?
Does ambrisentan improve outcomes in patients with pulmonary arterial hypertension?
Ambrisentan is an effective and safe treatment for pulmonary arterial hypertension, particularly when used upfront in combination with tadalafil.
May support upfront ambrisentan-tadalafil in PAH; leaves open optimal long-term sequencing and generalizability.
Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH and connective tissue disease-associated PAH. Ambrisentan has been shown to improve exercise capacity and hemodynamics with an acceptable side-effect profile. It has also proven to be safely used in combination with other PAH-specific medications, especially with phosphodiesterase-5 inhibitors. In the recent randomized trial, AMBITION, it was shown that upfront combination therapy of ambrisentan and tadalafil significantly decreased the risk of clinical failure compared with monotherapy. This review describes the drug profile of ambrisentan and its safety and efficacy in the treatment of PAH.
No takes yet. Share an insight, caveat, or question.
Rivera‐Lebron et al. (2017) conducted a review in Pulmonary arterial hypertension. Ambrisentan was evaluated. Ambrisentan improves exercise capacity and hemodynamics in pulmonary arterial hypertension, and upfront combination with tadalafil significantly decreases the risk of clinical failure versus monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: